The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Eli Lilly (LLY) .Lilly currently has an average brokerage recomme ...

Eli Lilly And Co LLY is one of several companies benefitting from demand for weight loss drugs. The company is also seeing competition in the market including knockoff drugs that it said could be unsafe.What Happened: A recent report says Eli Lilly is seeking medical records of people who took knockoff weight loss drugs.The request, reported by Bloomberg, is being done for safety reasons according to the pharmaceutical company.Eli Lilly is building a case against businesses that are selling knockoffs of the ...

Eli Lilly (LLY) announced that its Alzheimer's disease (AD) drug Kisunla (donanemab) has been approved for use in Japan. The drug will treat early symptomatic AD in adults with mild cognitive impairment (MCI) and those with the mild dementia stage of AD, with confirmed amyloid pathology.Japan is the second major market in which Kisunla has been approved for use. LLY received its first approval for the drug in the United States this July.Both these approvals are based on data from the TRAILBLAZER-ALZ 2 phase ...

The opportunities for artificial intelligence (AI) to have an impact in the healthcare space are enormous.Over the last couple of years, artificial intelligence (AI) has emerged as the world's next megatrend. Thus far, breakthroughs in generative AI have mostly revolved around the technology industry.In particular, semiconductor specialist Nvidia is viewed as the engine powering the AI vehicle right now. Demand for its most powerful graphics processing units (GPUs) has been off the charts, and investors hav ...

Monthly EGBLYSS maintenance dosing sustained clear or almost-clear skin for up to three years in the vast majority of ADvocate 1 and 2 responders Nearly 87 percent of patients taking EBGLYSS did not require either high-potency topical corticosteroids or systemic treatments during the three-year studyThe safety profile at three years was consistent with the previously published two-year resultsINDIANAPOLIS, Sept. 25, 2024 /PRNewswire/ -- More than 80 percent of adults and adolescents with moderate-to-severe ...

Japan is the second major market where Kisunla has received approvalKisunla was first approved in the United States in July 2024INDIANAPOLIS, Sept. 24, 2024 /PRNewswire/ -- The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's treatment for adults with early symptomatic Alzheimer's disease (AD), which includes people with mild cognitive impairment (MCI) as well as peopl ...

Nvidia has been the hottest stock since the start of the AI revolution, and I see one particular healthcare business following a similar trajectory.Nov. 30, 2022, will go down as a defining moment in modern history. That's the day OpenAI released ChatGPT to the masses. Just like that, euphoria about artificial intelligence (AI) took over the world.One of the biggest beneficiaries of the AI boom has been semiconductor specialist Nvidia. If you had bought shares of Nvidia on the same day that ChatGPT was intr ...

I am a full-time analyst interested in a wide range of stocks. With my unique insights and knowledge, I hope to provide other investors with a contrasting view of my portfolio, given my particular background.If you have any questions, feel free to reach out to me via a direct message on Seeking Alpha or leave a comment on one of my articles.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the ...

History shows that Eli Lilly tends to do something special with its stock toward the end of the year.With a market capitalization of over $800 billion, Eli Lilly (LLY 0.70%) is the largest pharmaceutical company in the world. Much that is thanks to the rise of glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro and Zepbound, which are fueling a new wave of growth for the company.Over the past 12 months, its shares have soared 58% -- nearly double the gains generated from the S&P 500 and Nasdaq Composi ...

JR Research is an opportunistic investor. He was recognized by TipRanks as a Top Analyst. He was also recognized by Seeking Alpha as a "Top Analyst To Follow" for Technology, Software, and Internet, as well as for Growth and GARP. He identifies attractive risk/reward opportunities supported by robust price action to potentially generate alpha well above the S&P 500. He has also demonstrated outperformance with his picks. He focuses on identifying growth investing opportunities that present the most attracti ...